Tag:
LXR-623
Latest Headlines
Latest Headlines
Wyeth drops Karo Bio atherosclerosis drug
Karo Bio and research partner Wyeth Pharmaceuticals have abandon development of LXR-623, a Phase I compound for atherosclerosis. According to a release, LXR-623 demonstrated efficacy on biomarkers
